Boron neutron capture enhancement of 252Cf brachytherapy

Beach, J.L.; Schroy, Carter B.; Ashtari, Manzar; Harris, Michael R.; Maruyama, Yosh

doi:10.1016/0360-3016(90)90317-d

Cited by 24 publications

(6 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Intriguingly, the development of remote afterloading techniques has regenerated interest in isotopes with much higher energy such as 252Cf, 198Au and 60Co, as these devices eliminate the worry of excessive radiation exposure to surrounding people and make it possible to deliver high doses over minutes to hours or for the fractionation of BRT (Beach et al 1990;Kolotas et al 1999).…”

Section: Controversy 1: Choice Of Radioactive Sourcesmentioning

confidence: 99%

Controversies concerning the application of brachytherapy in central nervous system tumors

Cheng

Zhang

2009

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

Section: Controversy 1: Choice Of Radioactive Sourcesmentioning

confidence: 99%

Controversies concerning the application of brachytherapy in central nervous system tumors

Cheng

Zhang

2009

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

“…It is a man-made nuclide which emits at a neutron rate of 2.31 × 10 12 neutrons/s per g. 87 252 Cf spontaneously emits a fission spectrum of neutrons with an average energy of 2.35 MeV and a yield of 3.76 neutrons per fission. 88 The dose rate obtainable based on a very large (1.0 g) source of 252 Cf is 4.1 RBE cGy/ min. 89 Furthermore, gamma rays with a mean energy of 1 MeV are emitted.…”

Section: Neutron Sources For Nctmentioning

confidence: 99%

Physical, dosimetric and clinical aspects and delivery systems in neutron capture therapy

Farhood

Samadian

Ghorbani

et al. 2018

Reports of Practical Oncology & Radiotherapy

View full text Add to dashboard Cite

Neutron capture therapy (NCT) is a targeted radiotherapy for cancer treatment. In this method, neutrons with a spectra/specific energy (depending on the type of agent used for NCT) are captured with an agent that has a high cross-section with these neutrons. There are some agents that have been proposed in NCT including B,Gd and S. Among these agents, onlyB is used in clinical trials. Application of Gd is limited to in-vivo and in-vitro research. In addition,S has been applied in the field of Monte Carlo simulation. In BNCT, the only two delivery agents which are presently applied in clinical trials are BPA and BSH, but other delivery systems are being developed for more effective treatment in NCT. Neutron sources used in NCT are fission reactors, accelerators, and Cf. Among these, fission reactors have the most application in NCT. So far, BNCT has been applied to treat various cancers including glioblastoma multiforme, malignant glioma, malignant meningioma, liver, head and neck, lung, colon, melanoma, thyroid, hepatic, gastrointestinal cancer, and extra-mammary Paget's disease. This paper aims to review physical, dosimetric and clinical aspects as well as delivery systems in NCT for various agents.

show abstract

“…Yet another alternative to create neutrons is by use of neutron-emitting radionuclides such as 2S2Cf (84,90) which has been used in some centres for treatment of cervical carinoma. One possibility for BNCT could be to find a tumour-specific boron compound (e.g.…”

Section: Neutron Beamsmentioning

confidence: 99%